<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751578</url>
  </required_header>
  <id_info>
    <org_study_id>CRD1020</org_study_id>
    <nct_id>NCT04751578</nct_id>
  </id_info>
  <brief_title>Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks - Netherlands</brief_title>
  <acronym>AAA-SHAPE_NLD</acronym>
  <official_title>Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks - A Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shape Memory Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shape Memory Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of IMPEDE-FX Embolization Plug and/or IMPEDE-FX Rapid&#xD;
      Fill to fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm&#xD;
      repair (EVAR) stent graft.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of related major adverse events (MAEs)</measure>
    <time_frame>30 days post-procedure</time_frame>
    <description>Incidence of related major adverse events (MAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy - Technical Success</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>Technical success, defined as filling of the residual flow lumen of the AAA sac with investigational products</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of related major adverse events (MAEs)</measure>
    <time_frame>2 years post-procedure</time_frame>
    <description>Incidence of related major adverse events (MAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of related serious adverse events (SAEs)</measure>
    <time_frame>2 years post-procedure</time_frame>
    <description>Incidence of related serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Type II endoleaks</measure>
    <time_frame>2 years post-procedure</time_frame>
    <description>Incidence of type II endoleaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Type I and type III endoleaks</measure>
    <time_frame>2 years post-procedure</time_frame>
    <description>Incidence of type I and type III endoleaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - AAA sac diameter/volume</measure>
    <time_frame>2 years post-procedure</time_frame>
    <description>Change in AAA sac diameter/volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Open repair</measure>
    <time_frame>2 years post-procedure</time_frame>
    <description>Rate of conversion to open AAA repair</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Reinterventions</measure>
    <time_frame>2 years post-procedure</time_frame>
    <description>Rate of other reinterventions related to the AAA sac growth and/or complications</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IMPEDE-FX Embolization Plug</intervention_name>
    <description>Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  A candidate for elective EVAR of an infrarenal aortic aneurysm ≥5.5 cm in diameter in&#xD;
             men and ≥5.0 cm in women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An inability to provide informed consent&#xD;
&#xD;
          -  Enrolled in another clinical study&#xD;
&#xD;
          -  Aortoiliac aneurysm, or concomitant iliac artery ectasia or aneurysm (common iliac&#xD;
             artery diameter &gt;24 mm) close to the bifurcation and/or that cannot be adequately&#xD;
             sealed&#xD;
&#xD;
          -  Patent AAA sac feeding vessels (within the sac) &gt;4 mm in diameter&#xD;
&#xD;
          -  Volume of AAA sac to be filled after stent graft placement &lt;20 mL or &gt;135 mL, based on&#xD;
             pre-procedure CTA (i.e. aortic flow volume exclusive of stent graft volume)&#xD;
&#xD;
          -  Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Cook&#xD;
             Zenith Flex AAA Endovascular Graft, or Medtronic Endurant II Stent Graft to treat the&#xD;
             AAA&#xD;
&#xD;
          -  Planned use of the chosen stent graft outside its instructions for use (IFU)&#xD;
&#xD;
          -  Planned use of fenestrated or chimney stent grafts&#xD;
&#xD;
          -  Study participants in which stent graft placement is abandoned for any reason, and/or&#xD;
             in which the investigator decides, during the course of the stent graft placement,&#xD;
             that the study procedure may not be appropriate&#xD;
&#xD;
          -  Planned use of embolic devices other than the investigational product to embolize the&#xD;
             AAA sac&#xD;
&#xD;
          -  Vascular disease and/or anatomy that preclude the safe access and positioning of a&#xD;
             catheter to deliver the investigational product into the AAA sac&#xD;
&#xD;
          -  Ruptured, leaking, or mycotic (infected) aneurysm&#xD;
&#xD;
          -  Aneurysmal disease of the descending thoracic aorta&#xD;
&#xD;
          -  Coagulopathy or uncontrolled bleeding disorder&#xD;
&#xD;
          -  Long-term (&gt;6 months prior to the procedure) use of direct oral anticoagulant or any&#xD;
             vitamin K antagonist anticoagulant use&#xD;
&#xD;
          -  Serum creatinine level &gt;2.5 mg/dL;&#xD;
&#xD;
          -  Cerebrovascular accident within 3 months prior to the procedure&#xD;
&#xD;
          -  Myocardial infarction and/or major heart surgery within 3 months prior to the&#xD;
             procedure&#xD;
&#xD;
          -  Atrial fibrillation that is not well rate controlled&#xD;
&#xD;
          -  Unable or unwilling to comply with study follow-up requirements&#xD;
&#xD;
          -  Life expectancy of &lt;2 years post-procedure&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to platinum, iridium, or polyurethane&#xD;
&#xD;
          -  A condition that inhibits radiographic visualization during the implantation procedure&#xD;
&#xD;
          -  History of allergy to contrast medium that cannot be managed medically&#xD;
&#xD;
          -  Uncontrolled co-morbid medical condition, including mental health issues, that would&#xD;
             adversely affect participation in the study&#xD;
&#xD;
          -  Pregnant or a lactating female. For females of child-bearing potential, based on a&#xD;
             positive pregnancy test within 7 days prior to the procedure or refusal to use a&#xD;
             medically accepted method of birth control for the duration of the study&#xD;
&#xD;
          -  Prisoner or member of other vulnerable population.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daphne van der Veen</last_name>
      <phone>(+31) 88 - 005 7282</phone>
      <email>dvanderveen@rijnstate.nl</email>
    </contact>
    <investigator>
      <last_name>Michel Reijnen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ETZ Elisabeth</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Van Hees</last_name>
      <phone>+31 13 221 2132</phone>
      <email>k.vanhees@etz.nl</email>
    </contact>
    <investigator>
      <last_name>Jan Heyligers, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
    <mesh_term>Endoleak</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

